Effect of the IL-1 Receptor Antagonist Kineret® on Disease Phenotype in mdx Mice

PLoS ONE

Volumn 11, Issue 5, 2016, Pages

  Klimek, Margaret E Benny ^a   Sali, Arpana ^a   Rayavarapu, Sree ^a   Nagaraju, Kanneboyina ^a,b  

^a CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^b GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; IL1B PROTEIN, MOUSE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR; BODY MASS; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DUCHENNE MUSCULAR DYSTROPHY; ENZYME INHIBITION; ENZYME RELEASE; EXTENSOR DIGITORUM LONGUS MUSCLE; FEMALE; FORELIMB; GRIP STRENGTH; HINDLIMB; HISTOLOGY; IN VITRO STUDY; MOTOR COORDINATION; MOUSE; MOVEMENT TIME; MUSCLE FUNCTION; MUSCLE MASS; MUSCLE STRENGTH; MUSCLE TWITCH; MUSCULOSKELETAL SYSTEM PARAMETERS; NONHUMAN; PHENOTYPE; RECEPTOR BLOCKING; SIGNAL TRANSDUCTION; SPLEEN CELL; TOTAL DISTANCE; X CHROMOSOME LINKED MUSCULAR DYSTROPHIC MOUSE; ANIMAL; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; HUMAN; IMMUNOLOGY; LOCOMOTION; METABOLISM; MOTOR ACTIVITY; MUSCULAR DYSTROPHY, DUCHENNE; PATHOPHYSIOLOGY; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FORELIMB; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1BETA; LOCOMOTION; MICE; MICE, INBRED MDX; MOTOR ACTIVITY; MUSCULAR DYSTROPHY, DUCHENNE; SIGNAL TRANSDUCTION;

EID: 84971280768     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0155944     Document Type: Article

References (52)

1. Hoffman EP, Brown RH Jr., Kunkel LM (1987) Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 51: 919-928. PMID: 3319190
2. Hoffman EP, Knudson CM, Campbell KP, Kunkel LM (1987) Subcellular fractionation of dystrophin to the triads of skeletal muscle. Nature 330: 754-758. PMID: 2447503
3. Hoffman EP, Monaco AP, Feener CC, Kunkel LM (1987) Conservation of the Duchenne muscular dystrophy gene in mice and humans. Science 238: 347-350. PMID: 3659917
4. Manzur AY, Kinali M, Muntoni F (2008) Update on the management of Duchenne muscular dystrophy. Arch Dis Child 93: 986-990. doi: 10.1136/adc.2007.118141 PMID: 18667451
5. Manzur AY, Kuntzer T, Pike M, Swan A (2008) Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane Database Syst Rev: CD003725. doi: 10.1002/14651858.CD003725.pub3 PMID: 18254031
6. Markham LW, Kinnett K, Wong BL, Woodrow Benson D, Cripe LH (2008) Corticosteroid treatment retards development of ventricular dysfunction in Duchenne muscular dystrophy. Neuromuscular disorders: NMD 18: 365-370. doi: 10.1016/j.nmd.2008.03.002 PMID: 18436445
7. Bulfield G, Siller WG, Wight PA, Moore KJ (1984) X chromosome-linked muscular dystrophy (mdx) in the mouse. Proceedings of the National Academy of Sciences of the United States of America 81: 1189-1192. PMID: 6583703
8. Grounds MD, Radley HG, Lynch GS, Nagaraju K, De Luca A (2008) Towards developing standard operating procedures for pre-clinical testing in the mdx mouse model of Duchenne muscular dystrophy. Neurobiol Dis 31: 1-19. doi: 10.1016/j.nbd.2008.03.008 PMID: 18499465
9. Tanabe Y, Esaki K, Nomura T (1986) Skeletal muscle pathology in X chromosome-linked muscular dystrophy (mdx) mouse. Acta neuropathologica 69: 91-95. PMID: 3962599
10. Huang P, Zhao XS, Fields M, Ransohoff RM, Zhou L (2009) Imatinib attenuates skeletal muscle dystrophy in mdx mice. FASEB journal: official publication of the Federation of American Societies for Experimental Biology 23: 2539-2548.
11. Heier CR, Damsker JM, Yu Q, Dillingham BC, Huynh T, Van der Meulen JH, et al. (2013) VBP15, a novel anti-inflammatory and membrane-stabilizer, improves muscular dystrophy without side effects. EMBO Mol Med 5: 1569-1585. doi: 10.1002/emmm.201302621 PMID: 24014378
12. Messina S, Bitto A, Aguennouz M, Minutoli L, Monici MC, Altavilla D, et al. (2006) Nuclear factor kappa-B blockade reduces skeletal muscle degeneration and enhances muscle function in Mdx mice. Experimental neurology 198: 234-241. PMID: 16410003
13. Tang Y, Reay DP, Salay MN, Mi MY, Clemens PR, Guttridge DC, et al. (2010) Inhibition of the IKK/NFkappaB pathway by AAV gene transfer improves muscle regeneration in older mdx mice. Gene Ther 17: 1476-1483. doi: 10.1038/gt.2010.110 PMID: 20720575
14. Barros Maranhao J, de Oliveira Moreira D, Mauricio AF, de Carvalho SC, Ferretti R, Pereira JA, et al. (2015) Changes in calsequestrin, TNF-alpha, TGF-beta and MyoD levels during the progression of skeletal muscle dystrophy in mdx mice: a comparative analysis of the quadriceps, diaphragm and intrinsic laryngeal muscles. Int J Exp Pathol 96: 285-293. doi: 10.1111/iep.12142 PMID: 26515458
15. Pierno S, Nico B, Burdi R, Liantonio A, Didonna MP, Cippone V, et al. (2007) Role of tumour necrosis factor alpha, but not of cyclo-oxygenase-2-derived eicosanoids, on functional and morphological indices of dystrophic progression in mdx mice: a pharmacological approach. Neuropathol Appl Neurobiol 33: 344-359. PMID: 17493014
16. de Senzi Moraes Pinto R, Ferretti R, Moraes LH, Neto HS, Marques MJ, Minatel E (2013) N-acetylcysteine treatment reduces TNF-alpha levels and myonecrosis in diaphragm muscle of mdx mice. Clin Nutr 32: 472-475. doi: 10.1016/j.clnu.2012.06.001 PMID: 22727548
17. Machado RV, Mauricio AF, Taniguti AP, Ferretti R, Neto HS, Marques MJ (2011) Eicosapentaenoic acid decreases TNF-alpha and protects dystrophic muscles of mdx mice from degeneration. J Neuroimmunol 232: 145-150. doi: 10.1016/j.jneuroim.2010.10.032 PMID: 21131061
18. Piers AT, Lavin T, Radley-Crabb HG, Bakker AJ, Grounds MD, Pinniger GJ (2011) Blockade of TNF in vivo using cV1q antibody reduces contractile dysfunction of skeletal muscle in response to eccentric exercise in dystrophic mdx and normal mice. Neuromuscul Disord 21: 132-141. doi: 10.1016/j.nmd. 2010.09.013 PMID: 21055937
19. Waters FJ, Shavlakadze T, McIldowie MJ, Piggott MJ, Grounds MD (2010) Use of pifithrin to inhibit p53-mediated signalling of TNF in dystrophic muscles of mdx mice. Mol Cell Biochem 337: 119-131. doi: 10.1007/s11010-009-0291-2 PMID: 19859789
20. Radley HG, Davies MJ, Grounds MD (2008) Reduced muscle necrosis and long-term benefits in dystrophic mdx mice after cV1q (blockade of TNF) treatment. Neuromuscul Disord 18: 227-238. doi: 10. 1016/j.nmd.2007.11.002 PMID: 18207402
21. Grounds MD, Davies M, Torrisi J, Shavlakadze T, White J, Hodgetts S (2005) Silencing TNFalpha activity by using Remicade or Enbrel blocks inflammation in whole muscle grafts: an in vivo bioassay to assess the efficacy of anti-cytokine drugs in mice. Cell Tissue Res 320: 509-515. PMID: 15846506
22. Grounds MD, Torrisi J (2004) Anti-TNFalpha (Remicade) therapy protects dystrophic skeletal muscle from necrosis. FASEB J 18: 676-682. PMID: 15054089
23. Rawat R, Cohen TV, Ampong B, Francia D, Henriques-Pons A, Hoffman EP, et al. (2010) Inflammasome up-regulation and activation in dysferlin-deficient skeletal muscle. The American journal of pathology 176: 2891-2900. doi: 10.2353/ajpath.2010.090058 PMID: 20413686
24. Dinarello CA (1996) Biologic basis for interleukin-1 in disease. Blood 87: 2095-2147. PMID: 8630372
25. Messina S, Altavilla D, Aguennouz M, Seminara P, Minutoli L, Monici MC, et al. (2006) Lipid peroxidation inhibition blunts nuclear factor-kappaB activation, reduces skeletal muscle degeneration, and enhances muscle function in mdx mice. The American journal of pathology 168: 918-926. PMID: 16507907
26. Huynh T, Uaesoontrachoon K, Quinn JL, Tatem KS, Heier CR, Van Der Meulen JH, et al. (2013) Selective modulation through the glucocorticoid receptor ameliorates muscle pathology in mdx mice. J Pathol 231: 223-235. doi: 10.1002/path.4231 PMID: 23794417
27. Angelini C, Pegoraro E, Turella E, Intino MT, Pini A, Costa C (1994) Deflazacort in Duchenne dystrophy: study of long-term effect. Muscle & nerve 17: 386-391.
28. Biggar WD, Harris VA, Eliasoph L, Alman B (2006) Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade. Neuromuscular disorders: NMD 16: 249-255. PMID: 16545568
29. Griggs RC, Moxley RT 3rd, Mendell JR, Fenichel GM, Brooke MH, Pestronk A, et al. (1991) Prednisone in Duchenne dystrophy. A randomized, controlled trial defining the time course and dose response. Clinical Investigation of Duchenne Dystrophy Group. Arch Neurol 48: 383-388. PMID: 2012511
30. Griggs RC, Moxley RT 3rd, Mendell JR, Fenichel GM, Brooke MH, Pestronk A, et al. (1993) Duchenne dystrophy: randomized, controlled trial of prednisone (18 months) and azathioprine (12 months). Neurology 43: 520-527. PMID: 8450994
31. Mendell JR, Moxley RT, Griggs RC, Brooke MH, Fenichel GM, Miller JP, et al. (1989) Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy. The New England journal of medicine 320: 1592-1597. PMID: 2657428
32. Aro AA, Freitas KM, Foglio MA, Carvalho JE, Dolder H, Gomes L, et al. (2013) Effect of the Arrabidaea chica extract on collagen fiber organization during healing of partially transected tendon. Life sciences 92: 799-807. doi: 10.1016/j.lfs.2013.02.011 PMID: 23454166
33. Spurney CF, Gordish-Dressman H, Guerron AD, Sali A, Pandey GS, Rawat R, et al. (2009) Preclinical drug trials in the mdx mouse: assessment of reliable and sensitive outcome measures. Muscle & nerve 39: 591-602.
34. Abbate A, Salloum FN, Vecile E, Das A, Hoke NN, Straino S, et al. (2008) Anakinra, a recombinant human interleukin-1 receptor antagonist, inhibits apoptosis in experimental acute myocardial infarction. Circulation 117: 2670-2683. doi: 10.1161/CIRCULATIONAHA.107.740233 PMID: 18474815
35. Mandrup-Poulsen T, Zumsteg U, Reimers J, Pociot F, Morch L, Helqvist S, et al. (1993) Involvement of interleukin 1 and interleukin 1 antagonist in pancreatic beta-cell destruction in insulin-dependent diabetes mellitus. Cytokine 5: 185-191. PMID: 8218929
36. Koivisto VA, Leirisalo-Repo M, Ebeling P, Tuominen JA, Knip M, Turunen U, et al. (1993) Seven years of remission in a type I diabetic patient. Diabetes care 16: 990-995. PMID: 8359107
37. Larsen CM, Faulenbach M, Vaag A, Ehses JA, Donath MY, Mandrup-Poulsen T (2009) Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes. Diabetes care 32: 1663-1668. doi: 10.2337/dc09-0533 PMID: 19542207
38. Lacraz G, Giroix MH, Kassis N, Coulaud J, Galinier A, Noll C, et al. (2009) Islet endothelial activation and oxidative stress gene expression is reduced by IL-1Ra treatment in the type 2 diabetic GK rat. PloS one 4: e6963. doi: 10.1371/journal.pone.0006963 PMID: 19742300
39. Mertens M, Singh JA (2009) Anakinra for rheumatoid arthritis: a systematic review. J Rheumatol 36: 1118-1125. doi: 10.3899/jrheum.090074 PMID: 19447938
40. Bresnihan B, Alvaro-Gracia JM, Cobby M, Doherty M, Domljan Z, Emery P, et al. (1998) Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis and rheumatism 41: 2196-2204. PMID: 9870876
41. Dalgic B, Egritas O, Sari S, Cuisset L (2007) A variant Muckle-Wells syndrome with a novel mutation in CIAS1 gene responding to anakinra. Pediatric nephrology 22: 1391-1394. PMID: 17486372
42. So A, De Smedt T, Revaz S, Tschopp J (2007) A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis research & therapy 9: R28.
43. Petrasek J, Bala S, Csak T, Lippai D, Kodys K, Menashy V, et al. (2012) IL-1 receptor antagonist ameliorates inflammasome-dependent alcoholic steatohepatitis in mice. J Clin Invest 122: 3476-3489. doi: 10.1172/JCI60777 PMID: 22945633
44. Tringali G, Dello Russo C, Preziosi P, Navarra P (2000) Interleukin-1 in the central nervous system: from physiology to pathology. Therapie 55: 171-175. PMID: 10860021
45. Minami M, Kuraishi Y, Yamaguchi T, Nakai S, Hirai Y, Satoh M (1991) Immobilization stress induces interleukin-1 beta mRNA in the rat hypothalamus. Neurosci Lett 123: 254-256. PMID: 2027540
46. Cragnolini AB, Schioth HB, Scimonelli TN (2006) Anxiety-like behavior induced by IL-1beta is modulated by alpha-MSH through central melanocortin-4 receptors. Peptides 27: 1451-1456. PMID: 16325304
47. Nguyen KT, Deak T, Owens SM, Kohno T, Fleshner M, Watkins LR, et al. (1998) Exposure to acute stress induces brain interleukin-1beta protein in the rat. J Neurosci 18: 2239-2246. PMID: 9482808
48. Koo JW, Duman RS (2009) Interleukin-1 receptor null mutant mice show decreased anxiety-like behavior and enhanced fear memory. Neurosci Lett 456: 39-43. doi: 10.1016/j.neulet.2009.03.068 PMID: 19429130
49. Wakabayashi C, Numakawa T, Odaka H, Ooshima Y, Kiyama Y, Manabe T, et al. (2015) IL-1 receptorantagonist (IL-1Ra) knockout mice show anxiety-like behavior by aging. Neurosci Lett 599: 20-25. doi: 10.1016/j.neulet.2015.05.019 PMID: 26002078
50. Hein AM, Zarcone TJ, Parfitt DB, Matousek SB, Carbonari DM, Olschowka JA, et al. (2012) Behavioral, structural and molecular changes following long-term hippocampal IL-1beta overexpression in transgenic mice. J Neuroimmune Pharmacol 7: 145-155. doi: 10.1007/s11481-011-9294-3 PMID: 21748283
51. Ermolova NV, Martinez L, Vetrone SA, Jordan MC, Roos KP, Sweeney HL, et al. (2014) Long-term administration of the TNF blocking drug Remicade (cV1q) to mdx mice reduces skeletal and cardiac muscle fibrosis, but negatively impacts cardiac function. Neuromuscul Disord 24: 583-595. doi: 10. 1016/j.nmd.2014.04.006 PMID: 24844454
52. Yilmaz-Elis AS, Aartsma-Rus A, t Hoen PA, Safdar H, Breukel C, van Vlijmen BJ, et al. (2013) Inhibition of IL-1 Signaling by Antisense Oligonucleotide-mediated Exon Skipping of IL-1 Receptor Accessory Protein (IL-1RAcP). Mol Ther Nucleic Acids 2: e66. doi: 10.1038/mtna.2012.58 PMID: 23340324